The E3 ubiquitin ligase TRAF2 can contribute to TNF-α resistance in FLT3-ITD-positive AML cells

Leukemia Research

Volumn 37, Issue 11, 2013, Pages 1557-1564

  Schnetzke, Ulf ^a   Fischer, Mike ^a   Spies Weisshart, Bärbel ^a   Zirm, Elisabeth ^a   Hochhaus, Andreas ^a   Müller, Jörg P ^a   Scholl, Sebastian ^a  

^a JENA UNIVERSITY HOSPITAL   (Germany)

Author keywords

AC220; AML; FLT3 ITD; TNF ; TRAF2

Indexed keywords

GLYCOGEN SYNTHASE KINASE 3BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LENTIVIRUS VECTOR; PROTEIN KINASE B; QUIZARTINIB; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 2; VASCULOTROPIN RECEPTOR 1; CD135 ANTIGEN; FLT3 PROTEIN, HUMAN; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 BETA; MESSENGER RNA; SMALL INTERFERING RNA;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; CANCER CELL DESTRUCTION; CELL SURVIVAL; CONTROLLED STUDY; DOWN REGULATION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; INTRACELLULAR SIGNALING; LENTIVIRINAE; LEUKEMIA CELL LINE; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; AML; APOPTOSIS; CELL PROLIFERATION; DRUG ANTAGONISM; DRUG RESISTANCE; FLT3-ITD; GENETICS; METABOLISM; PATHOLOGY; PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TANDEM REPEAT; TNF-Α; TUMOR CELL CULTURE; WESTERN BLOTTING; ACUTE MYELOBLASTIC LEUKEMIA; ANTAGONISTS AND INHIBITORS;

AC220; AML; FLT3-ITD; TNF-Α; TRAF2;

APOPTOSIS; BLOTTING, WESTERN; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; FMS-LIKE TYROSINE KINASE 3; GLYCOGEN SYNTHASE KINASE 3; HUMANS; LEUKEMIA, MYELOID, ACUTE; NF-KAPPA B; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TANDEM REPEAT SEQUENCES; TNF RECEPTOR-ASSOCIATED FACTOR 2; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84886775237     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2013.08.004     Document Type: Article

References (38)

1. Sanders M.A., Valk P.J. The evolving molecular genetic landscape in acute myeloid leukaemia. Curr Opin Hematol 2013, 20:79-85.
2. Yang J., Schiffer C.A. Genetic biomarkers in acute myeloid leukemia: will the promise of improving treatment outcomes be realized. Expert Rev Hematol 2012, 5:395-407.
3. Nakao M., Yokota S., Iwai T., Kaneko H., Horiike S., Kashima K., et al. Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia 1996, 10:1911-1918.
4. Yokota S., Kiyoi H., Nakao M., Iwai T., Misawa S., Okuda T., et al. Internal tandem duplication of the FLT3 gene is preferentially seen in acute myeloid leukemia and myelodysplastic syndrome among various hematological malignancies. A study on a large series of patients and cell lines. Leukemia 1997, 11:1605-1609.
5. Kottaridis P.D., Gale R.E., Frew M.E., Harrison G., Langabeer S.E., Belton A.A., et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood 2001, 98:1752-1759.
6. Schnittger S., Schoch C., Dugas M., Kern W., Staib P., Wuchter C., et al. Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood 2002, 100:59-66.
7. Thiede C., Steudel C., Mohr B., Schaich M., Schakel U., Platzbecker U., et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood 2002, 99:4326-4335.
8. Brandts C.H., Sargin B., Rode M., Biermann C., Lindtner B., Schwable J., et al. Constitutive activation of Akt by Flt3 internal tandem duplications is necessary for increased survival, proliferation, and myeloid transformation. Cancer Res 2005, 65:9643-9650.
9. Hayakawa F., Towatari M., Kiyoi H., Tanimoto M., Kitamura T., Saito H., et al. Tandem-duplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines. Oncogene 2000, 19:624-631.
10. Guzman M.L., Neering S.J., Upchurch D., Grimes B., Howard D.S., Rizzieri D.A., et al. Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells. Blood 2001, 98:2301-2307.
11. Guzman M.L., Swiderski C.F., Howard D.S., Grimes B.A., Rossi R.M., Szilvassy S.J., et al. Preferential induction of apoptosis for primary human leukemic stem cells. Proc Natl Acad Sci USA 2002, 99:16220-16225.
12. Grosjean-Raillard J., Ades L., Boehrer S., Tailler M., Fabre C., Braun T., et al. Flt3 receptor inhibition reduces constitutive NFkappaB activation in high-risk myelodysplastic syndrome and acute myeloid leukemia. Apoptosis 2008, 13:1148-1161.
13. Elbaz O., Mahmoud L.A., Touw I.P., Lowenberg B. Analysis of the TNF receptors on human leukaemia cells by affinity cross-linking. Br J Haematol 1992, 81:530-532.
14. Delwel R., van Buitenen C., Lowenberg B., Touw I. Involvement of tumor necrosis factor (TNF) receptors p55 and p75 in TNF responses of acute myeloid leukemia blasts in vitro. Blood 1992, 80:1798-1803.
15. Elbaz O., Budel L.M., Hoogerbrugge H., Touw I.P., Delwel R., Mahmoud L.A., et al. Tumor necrosis factor downregulates granulocyte-colony-stimulating factor receptor expression on human acute myeloid leukemia cells and granulocytes. J Clin Invest 1991, 87:838-841.
16. Brailly H., Pebusque M.J., Tabilio A., Mannoni P. TNF alpha acts in synergy with GM-CSF to induce proliferation of acute myeloid leukemia cells by up-regulating the GM-CSF receptor and GM-CSF gene expression. Leukemia 1993, 7:1557-1563.
17. Aggarwal B.B., Gupta S.C., Kim J.H. Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey. Blood 2012, 119:651-665.
18. Karin M., Lin A. NF-kappaB at the crossroads of life and death. Nat Immunol 2002, 3:221-227.
19. Giri D.K., Aggarwal B.B. Constitutive activation of NF-kappaB causes resistance to apoptosis in human cutaneous T cell lymphoma HuT-78 cells. Autocrine role of tumor necrosis factor and reactive oxygen intermediates. J Biol Chem 1998, 273:14008-14014.
20. Rushworth S.A., MacEwan D.J. HO-1 underlies resistance of AML cells to TNF-induced apoptosis. Blood 2008, 111:3793-3801.
21. Ha H., Han D., Choi Y. TRAF-mediated TNFR-family signaling. Current protocols in immunology 2009, Chapter 11: Unit11 9D. J.E. Coligan (Ed.).
22. Chung J.Y., Lu M., Yin Q., Wu H. Structural revelations of TRAF2 function in TNF receptor signaling pathway. Adv Exp Med Biol 2007, 597:93-113.
23. Wajant H., Scheurich P. TNFR1-induced activation of the classical NF-kappaB pathway. FEBS J 2011, 278:862-876.
24. Aggarwal B.B. Nuclear factor-kappaB: the enemy within. Cancer Cell 2004, 6:203-208.
25. Sawanobori M., Yamaguchi S., Hasegawa M., Inoue M., Suzuki K., Kamiyama R., et al. Expression of TNF receptors and related signaling molecules in the bone marrow from patients with myelodysplastic syndromes. Leuk Res 2003, 27:583-591.
26. Zirm E., Spies-Weisshart B., Heidel F., Schnetzke U., Bohmer F.D., Hochhaus A., et al. Ponatinib may overcome resistance of FLT3-ITD harbouring additional point mutations, notably the previously refractory F691I mutation. Br J Haematol 2012, 157:483-492.
27. Buchner T., Schlenk R.F., Schaich M., Dohner K., Krahl R., Krauter J., et al. Acute myeloid leukemia (AML): different treatment strategies versus a common standard arm - combined prospective analysis by the German AML Intergroup. J Clin Oncol 2012, 30:3604-3610.
28. Schnetzke U., Fischer M., Kuhn A.K., Spies-Weisshart B., Zirm E., Hochhaus A., et al. The E3 ubiquitin ligase TRAF6 inhibits LPS-induced AKT activation in FLT3-ITD-positive MV4-11 AML cells. J Cancer Res Clin Oncol 2012.
29. Ren X., Xu Z., Myers J.N., Wu X. Bypass NFkappaB-mediated survival pathways by TRAIL and Smac. Cancer Biol Therapy 2007, 6:1031-1035.
30. Dai Y., Lawrence T.S., Xu L. Overcoming cancer therapy resistance by targeting inhibitors of apoptosis proteins and nuclear factor-kappa B. Am J Transl Res 2009, 1:1-15.
31. Jackson-Bernitsas D.G., Ichikawa H., Takada Y., Myers J.N., Lin X.L., Darnay B.G., et al. Evidence that TNF-TNFR1-TRADD-TRAF2-RIP-TAK1-IKK pathway mediates constitutive NF-kappaB activation and proliferation in human head and neck squamous cell carcinoma. Oncogene 2007, 26:1385-1397.
32. Bottero V., Imbert V., Frelin C., Formento J.L., Peyron J.F. Monitoring NF-kappa B transactivation potential via real-time PCR quantification of I kappa B-alpha gene expression. Mol Diagn 2003, 7:187-194.
33. Gu L., Findley H.W., Zhu N., Zhou M. Endogenous TNFalpha mediates cell survival and chemotherapy resistance by activating the PI3K/Akt pathway in acute lymphoblastic leukemia cells. Leukemia 2006, 20:900-904.
34. Li X., Yang Y., Ashwell J.D. TNF-RII and c-IAP1 mediate ubiquitination and degradation of TRAF2. Nature 2002, 416:345-347.
35. Yang H.J., Youn H., Seong K.M., Jin Y.W., Kim J., Youn B. Phosphorylation of ribosomal protein S3 and antiapoptotic TRAF2 protein mediates radioresistance in non-small cell lung cancer cells. J Biol Chem 2013, 288:2965-2975.
36. Naude P.J., den Boer J.A., Luiten P.G., Eisel U.L. Tumor necrosis factor receptor cross-talk. FEBS J 2011, 278:888-898.
37. Zarrinkar P.P., Gunawardane R.N., Cramer M.D., Gardner M.F., Brigham D., Belli B., et al. AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML). Blood 2009, 114:2984-2992.
38. Damas P., Reuter A., Gysen P., Demonty J., Lamy M., Franchimont P. Tumor necrosis factor and interleukin-1 serum levels during severe sepsis in humans. Crit Care Med 1989, 17:975-978.